Neuropsychiatric SLE - 2/3 Improved at 12 Months Save
The management and outcomes of neuropsychiatric systemic lupus erythematosus (NPSLE) can be challenging as there is limited data.
A retrospective cohort study identified 350 NPSLE events (between 1999-2015) defined by ACR definitions and categorized as being: central/diffuse, central/focal and peripheral. Clinical outcomes and predictors of clinical improvement/resolution were investigated.
NPSLE patients had an average age of 40 years. The diagnosis of NP-SLE (OR 4.32) and a SLEDAI-2K scores of at least 6 (OR 5.64) increased likelihood of initiating immunosuppressive therapy for NP events. Other takeaways from this study:
- Immunosuppressants and corticosteroids were frequently initiated/escalated for central diffuse or focal NP manifestations
- At 12 months, two-thirds (64%) showed a improvement in NP manifestations.
- Higher rated of improvement seen with Focal central NPSLE events
- NPSLE manifestations treated with immunosuppressants had higher odds of clinical response (OR 2.55)
- Age at diagnosis and focal central events emerged as additional response predictors.
Two-thirds of patients with NPSLE are improved by 12 mos. This is facilitated by NP diagnosis and treating with immunosuppressants.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.